OverviewSuggest Edit

BioInvent focuses on the discovery and development of antibody-based drugs against cancer. The Company's lead drug candidate is BI-1206, a human antibody targeting CD32b, an immunosuppressive protein that is expressed in patients with B-cell cancers. The BI-1206 drug is in Phase I/II clinical trials currently ongoing in patients with non-Hodgkin lymphoma and chronic lymphocytic leukaemia who are resistant to rituximab. It is also developing immuno-modulatory antibodies, such as cancer-associated regulatory T cells and tumour-associated myeloid-derived suppressor cells.

TypePublic
Founded1997
HQLund, SE
Websitebioinvent.com

Latest Updates

Employees (est.) (Feb 2021)73
Share Price (Apr 2021)KR49.8 (+4%)
Cybersecurity ratingBMore

Key People/Management at BioInvent

Martin Welschof

Martin Welschof

CEO
Kristoffer Rudenholm Hansson

Kristoffer Rudenholm Hansson

Senior Vice President, Technical Operations
Show more

BioInvent Office Locations

BioInvent has an office in Lund
Lund, SE (HQ)
The Gamma Building Sölvegatan 41
Lund, SE
Scheelevägen 17
Show all (2)

BioInvent Financials and Metrics

BioInvent Revenue

Market capitalization (7-Apr-2021)

2.0b

Closing stock price (7-Apr-2021)

49.8
BioInvent's current market capitalization is kr2 b.
Show all financial metrics

BioInvent Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

BioInvent Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

BioInvent Online and Social Media Presence

Embed Graph

BioInvent News and Updates

Resolution at the Extraordinary General Meeting in BioInvent on March 23, 2021

LUND, Sweden, March 23, 2021 /PRNewswire/ -- BioInvent International AB's (publ) ("BioInvent") (Nasdaq Stockholm: BINV) Extraordinary General Meeting (the "EGM") today resolved to approve the Board of Directors' resolution on a directed share issue of 16,260,601 new shares. The EGM...

BioInvent presents proof-of-concept data on anti-FcyRIIB antibody BI-1607 at AACR Annual Meeting 2021

LUND, Sweden, March 11, 2021 /PRNewswire/ -- BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), today announces the publication of proof-of-concept data on a novel, fully human FcγRIIB-blocking antibody, BI-1607, at the American Association for Cancer Research (AACR)...

BioInvent and Transgene has enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors

LUND, Sweden and STRASBOURG, France, March 1, 2021 /PRNewswire/ -- BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene...

BioInvent International Financial Statement January 1 - December 31, 2020

LUND, Sweden, Feb. 23, 2021 /PRNewswire/ -- "BioInvent has started 2021 with significant positive momentum We reported promising interim efficacy data from the ongoing Phase I/IIa trial of our lead drug candidate BI-1206.The company also closed a successful SEK 962 million financing...

BioInvent Phase I/IIa data suggest BI-1206 restores activity of rituximab in relapsed non-Hodgkin's lymphoma patients

LUND, Sweden, Jan. 28, 2021 /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces positive interim results from...

BioInvent has enrolled first patient in a Phase I/IIa trial of the first-in-class anti-TNFR2 antibody BI-1808 for the treatment of patients with solid tumors and CTCL

LUND, Sweden, Jan. 26, 2021 /PRNewswire/ -- BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces the enrollment...
Show more

BioInvent Frequently Asked Questions

  • When was BioInvent founded?

    BioInvent was founded in 1997.

  • Who are BioInvent key executives?

    BioInvent's key executives are Martin Welschof and Kristoffer Rudenholm Hansson.

  • How many employees does BioInvent have?

    BioInvent has 73 employees.

  • Who are BioInvent competitors?

    Competitors of BioInvent include Pharma Mar, A&G Pharmaceutical and Isotopen Technologien Munchen.

  • Where is BioInvent headquarters?

    BioInvent headquarters is located at The Gamma Building Sölvegatan 41, Lund.

  • Where are BioInvent offices?

    BioInvent has an office in Lund.

  • How many offices does BioInvent have?

    BioInvent has 2 offices.